Effect of arotinolol on left ventricular function in patients with idiopathic dilated cardiomyopathy.
- Author:
Chao-mei FAN
1
;
Hong YANG
;
Yi-shi LI
;
Li XU
;
Ke-fei DOU
;
Jing-lin ZHAO
;
Xian-qi YUAN
;
Yan-fen ZHAO
;
Rong-fang SHI
;
Xiu-qing DU
;
Na-qiang LU
Author Information
- Publication Type:Journal Article
- MeSH: Adrenergic beta-Antagonists; adverse effects; pharmacology; therapeutic use; Adult; Cardiomyopathy, Dilated; drug therapy; physiopathology; Echocardiography; Female; Humans; Male; Middle Aged; Propanolamines; adverse effects; pharmacology; therapeutic use; Ventricular Function, Left; drug effects
- From: Chinese Medical Sciences Journal 2007;22(4):224-227
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of long-term treatment with arotinolol in patients with idiopathic dilated cardiomyopathy (IDCM).
METHODSSixty-three patients with IDCM were evaluated at baseline and after 12-month therapy with arotinolol. The conventional therapy for congestive heart failure was continued throughout the study with arotinolol as the only beta-blocker. Left ventricular function was assessed with the New York Heart Association functional class and two-dimensional echocardiography.
RESULTSAfter 12-month arotinolol treatment, there was a significant improvement in left ventricular systolic function. Left ventricular end-systolic dimension significantly decreased from 59.52 +/- 8.83 mm to 50.89 +/- 8.17 mm (P < 0.001). Left ventricular ejection fraction significantly increased from 27.39% +/- 7.94% to 41.13% +/- 9.45% ( P < 0.001). Left ventricular mass index decreased from 150.47 +/- 42.42 g/m2 to 141.58 +/- 34.36 g/m2 (P < 0.01). No adverse events leading to premature discontinuation of study drug occurred.
CONCLUSIONIn this preliminary study, 12-month arotinolol treatment has a favorable effect on left ventricular function in patients with IDCM, and it is safe and well tolerated.
